CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Sponsor
Liping Dou
Study ID
NCT07587840
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • CD22/CD19 CAR-T cell immunotherapy — BIOLOGICAL
    Autologous T cells were collected and genetically modified to express chimeric antigen receptors targeting CD19 and CD22. Following lymphodepleting chemotherapy, patients received a single intravenous infusion of CD19/CD22 CAR-T cells.

Study Details

The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.

Key Dates

First listed
May 14, 2026
Start date
Jan 1, 2026
Status verified
Apr 2026
Primary completion
Jan 1, 2027
Completion
Jan 1, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CD22/CD19 CAR-T cell immunotherapy
    patients with high-risk invasive Follicular Lymphoma who accept targeted CD22/CD19 CAR-T cell immunotherapy for first-line consolidation therapy

Primary Outcome Measure

1-year progression free survival rate (1-year-PFSR) [ Time Frame: 2 year after treatment ]

Central Contacts

Related Studies